Parc Activité La Poudrette Lamartine

4/6 Rue du Dauphiné

69120 Vaulx-en-Velin

France

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F .........X........ Form 40-F.................

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ............ No .....X.....

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date :

EDAP TMS S.A.

IAN VAWTER

CHIEF FINANCIAL OFFICER

EDAP TMS S.A. Confirms its Listing on the

United States NASDAQ National Market System

Vaulx-en-Velin, France, April 2, 2002 EDAP TMS S.A. (NASDAQ and NASDAQ Europe: EDAP) a global leader in the development, marketing and distribution of a portfolio of minimally-invasive medical devices for the treatment of urological diseases today reiterates its continued listing on the U.S. NASDAQ National Market System. The Company reassures its shareholders that it remains committed to increasing its visibility and the value of its share price on the U.S. NASDAQ National Market System.

EDAP TMS S.A., is the global leader in the development, production, marketing and distribution of a portfolio of minimally invasive medical devices primarily for the treatment of urological diseases. The Company currently produces and markets devices for the minimally invasive treatment of localized prostate cancer, using High Intensity Focused Ultrasound (HIFU) and the treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL). The Company also produces and markets in Japan and Italy devices for the non-surgical treatment of benign Prostate Hyperplasia (BPH) using Microwave Thermotherapy (TUMT). The Company is also developing HIFU for the treatment of certain other types of tumors. For more information, in the U.S., contact EDAP Technomed Inc., the Company's U.S. subsidiary located in Atlanta, GA, by phone at (770) 446-9950.